An integrated single-cell RNA-seq map of human neuroblastoma tumors and preclinical models uncovers divergent mesenchymal-like gene expression programs

Richard H. Chapple,Xueying Liu,Sivaraman Natarajan,Margaret I.M. Alexander,Yuna Kim,Anand G. Patel,Christy W. LaFlamme,Min Pan,William C. Wright,Hyeong-Min Lee,Yinwen Zhang,Meifen Lu,Selene C. Koo,Courtney Long,John Harper,Chandra Savage,Melissa D. Johnson,Thomas Confer,Walter J. Akers,Michael A. Dyer,Heather Sheppard,John Easton,Paul Geeleher

DOI: https://doi.org/10.1101/2023.04.13.536639

2024-04-22

Abstract:Neuroblastoma is a common pediatric cancer, where preclinical studies suggest that a mesenchymal-like gene expression program contributes to chemotherapy resistance. However, clinical outcomes remain poor, implying we need a better understanding of the relationship between patient tumor heterogeneity and preclinical models. Here, we generated single-cell RNA-seq maps of neuroblastoma cell lines, patient-derived xenograft models (PDX), and a genetically engineered mouse model (GEMM). We developed an unsupervised machine learning approach (‘automatic consensus nonnegative matrix factorization’ (acNMF)) to compare the gene expression programs found in preclinical models to a large cohort of patient tumors. We confirmed a weakly expressed, mesenchymal-like program in otherwise adrenergic cancer cells in some pre-treated high-risk patient tumors, but this appears distinct from the presumptive drug-resistance mesenchymal programs evident in cell lines. Surprisingly however, this weak-mesenchymal-like program was maintained in PDX and could be chemotherapy-induced in our GEMM after only 24 hours, suggesting an uncharacterized therapy-escape mechanism. Collectively, our findings improve the understanding of how neuroblastoma patient tumor heterogeneity is reflected in preclinical models, provides a comprehensive integrated resource, and a generalizable set of computational methodologies for the joint analysis of clinical and pre-clinical single-cell RNA-seq datasets.

Cancer Biology

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to understand the relationship between tumor heterogeneity in neuroblastoma patients and pre - clinical models, especially for a mesenchymal - like gene expression program which is considered to be related to chemotherapy resistance. Although this mesenchymal - like gene expression program has been observed in cell lines and mouse models to potentially contribute to chemotherapy resistance, the clinical results are still poor, indicating that a deeper understanding of how patient tumor heterogeneity is reflected in pre - clinical models is required. Specifically, the researchers generated single - cell RNA sequencing maps of neuroblastoma cell lines, patient - derived xenograft models (PDX), and genetically engineered mouse models (GEMM), and developed an unsupervised machine - learning method - Automatic Consensus Non - negative Matrix Factorization (acNMF) - to compare the relationships between gene expression programs in these pre - clinical models and a large number of patient tumor samples. Through this method, they hope to confirm the form of the mesenchymal - like gene expression program in patient tumors, evaluate its performance consistency in different models, and explore whether this program can be induced as part of a treatment - escape mechanism. The key objectives of the paper include: 1. **Confirm the mesenchymal - like gene expression program**: Verify whether there is a weakly - expressed mesenchymal - like gene expression program in some pre - treated high - risk patient tumors. 2. **Evaluate the consistency of the models**: Compare the performance of gene expression programs in different pre - clinical models (such as cell lines, PDX, and GEMM), especially whether the mesenchymal - like program behaves consistently in these models. 3. **Explore the treatment - escape mechanism**: Investigate whether this weak mesenchymal - like program can be induced by chemotherapy in PDX models or GEMM, thereby revealing potential treatment - escape mechanisms. Through these analyses, the research aims to provide a comprehensive integrated resource and develop a set of general computational methods to jointly analyze clinical and pre - clinical single - cell RNA sequencing data sets, ultimately improving the understanding of tumor heterogeneity in neuroblastoma patients and guiding drug development.

An integrated single-cell RNA-seq map of human neuroblastoma tumors and preclinical models uncovers divergent mesenchymal-like gene expression programs

An integrated single-cell RNA-seq map of human neuroblastoma tumors and preclinical models uncovers divergent mesenchymal-like gene expression programs

Abstract 868: A novel unsupervised machine learning model applied to neuroblastoma single-cell RNA-seq data reveals a drug-induced mesenchymal-like gene expression program

Single-cell analyses of metastatic bone marrow in human neuroblastoma reveals microenvironmental remodeling and metastatic signature

A spatial cell atlas of neuroblastoma reveals developmental, epigenetic and spatial axis of tumor heterogeneity

Single-cell transcriptomics reveals shared immunosuppressive landscapes of mouse and human neuroblastoma

Single-cell RNA-seq reveals the transcriptional program underlying tumor progression and metastasis in neuroblastoma

Abstract 147: Identification of cell sub-populations in Neuroblastoma cell lines with single-cell-sequencing analysis

In Vivo Modeling of Chemoresistant Neuroblastoma Provides New Insights into Chemorefractory Disease and Metastasis

Simultaneous single-nucleus RNA sequencing and single-nucleus ATAC sequencing of neuroblastoma cell lines

Single-cell RNA sequencing explored potential therapeutic targets by revealing the tumor microenvironment of neuroblastoma and its expression in cell death

Lineage-dependence of the neuroblastoma surfaceome defines tumor cell state-dependent and independent immunotherapeutic targets

A highly malignant case of neuroblastoma with substantial increase of single-nucleotide variants and normal mismatch repair system: A case report.

Abstract 5466: In vivo characterization of neuroblastoma intratumoral heterogeneity

RNA-Seq Reveals Allele-Specific Expression of Somatic Mutations in Neuroblastoma

Joint single-cell genetic and transcriptomic analysis reveal pre-malignant SCP-like subclones in human neuroblastoma

Neuroblastoma patient‐derived cultures are enriched for a mesenchymal gene signature and reflect individual drug response

A mitochondria-related genes associated neuroblastoma signature - based on bulk and single-cell transcriptome sequencing data analysis, and experimental validation

Mutually exclusive teams-like patterns of gene regulation characterize phenotypic heterogeneity along the noradrenergic-mesenchymal axis in neuroblastoma

Transcriptional Profiling Reveals a Common Metabolic Program in High-Risk Human Neuroblastoma and Mouse Neuroblastoma Sphere-Forming Cells.

Integrated Genomic Profiling and Drug Screening of Patient-Derived Cultures Identifies Individualized Copy Number-Dependent Susceptibilities Involving PI3K Pathway and 17q Genes in Neuroblastoma